Bifidobacterium infantis VPro 53 and No Significant Adverse Events

• Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial

  • 2017-05-30
  • BMC Pediatrics 17(1)
  • • J. Smilowitz
    • Jackelyn Moya
    • Melissa A. Breck
    • Chelsea Cook
    • A. Fineberg
    • K. Angkustsiri
    • M. Underwood

  • PubMed: 28558732
  • DOI: 10.1186/s12887-017-0886-9

  13 Insights on

  • No Significant Adverse Events

  • Low evidence
  • Rigorous Journal

  None of the safety and tolerability endpoints, including flatulence, bloody stool, body temperature, ratings of gastrointestinal symptoms, use of antibiotics or gas-relieving medications, infant colic, jaundice, number of illnesses, sick doctor visits, or diagnoses of eczema were different for the groups at any point.

  Effect

  Neutral

  Effect size

  Large

  Significant

  No